Sean M. Healey & AMG Center for ALS Announces the Names of 54 Selected Sites for the HEALEY ALS Platform Trial
The Sean M. Healey & AMG Center at Massachusetts General Hospital, in collaboration with the Northeast ALS Consortium (NEALS), is launching the first platform trial for amyotrophic lateral sclerosis (ALS). The goals of this groundbreaking project are to greatly accelerate the timelines towards effective ALS treatments and provide greater trial access for all those affected by this disease. Visit the trial page on ClinicalTrials.gov for more information about sites and trial participation criteria.
The HEALEY ALS Platform Trial is a collaborative effort and enrollment in the trial will be available at several sites across the U.S. to bring the trial close to people who want to participate. All sites are part of the NEALS Consortium. See below for a list of participating sites.
For more information, please email healeycenterforals@mgh.harvard.edu.
List of Participating Sites
|
Site |
State |
|
Barrow Neurological Institute |
Arizona |
|
Forbes Norris MDA/ALS Research Center, California Pacific Medical Center |
California |
|
University of California, Irvine |
California |
|
Cedars-Sinai Medical Center |
California |
|
Loma Linda University Health |
California |
|
University of Colorado |
Colorado |
|
Hospital for Special Care |
Connecticut |
|
Phil Smith Neuroscience Institute at Holy Cross Hospital |
Florida |
|
Mayo Clinic Florida |
Florida |
|
University of Florida |
Florida |
|
University of Miami |
Florida |
|
University of South Florida |
Florida |
|
Emory University |
Georgia |
|
University of Chicago |
Illinois |
|
Northwestern University |
Illinois |
|
University of Iowa Hospitals and Clinics |
Iowa |
|
University of Kansas Medical Center |
Kansas |
|
University of Kentucky |
Kentucky |
|
Ochsner Health Systems |
Louisiana |
|
John Hopkins University |
Maryland |
|
University of Maryland |
Maryland |
|
Beth Israel Deaconess Medical Center |
Massachusetts |
|
Massachusetts General Hospital |
Massachusetts |
|
University of Massachusetts Medical School |
Massachusetts |
|
Henry Ford Health System |
Michigan |
|
University of Michigan |
Michigan |
|
Spectrum Health |
Michigan |
|
Mayo Clinic Rochester |
Minnesota |
|
University of Minnesota/Twin Cities ALS Research Consortium |
Minnesota |
|
University of Missouri Health Care |
Missouri |
|
Saint Louis University |
Missouri |
|
Washington University School of Medicine |
Missouri |
|
University of Nebraska Medical Center |
Nebraska |
|
Neurology Associates, P.C./Somnos Clinical Research |
Nebraska |
|
Dartmouth-Hitchcock Medical Center |
New Hampshire |
|
Columbia University |
New York |
|
SUNY Upstate |
New York |
|
Duke University |
North Carolina |
|
Wake Forest University Health Sciences |
North Carolina |
|
The Ohio State University |
Ohio |
|
Providence Brain and Spine Institute ALS Center |
Oregon |
|
University of Pennsylvania |
Pennsylvania |
|
Lewis Katz School of Medicine at Temple University |
Pennsylvania |
|
Jefferson Weinberg ALS Center, Thomas Jefferson University |
Pennsylvania |
|
Penn State Hershey |
Pennsylvania |
|
Medical University of South Carolina |
South Carolina |
|
Vanderbilt University Medical Center |
Tennessee |
|
Wesley Neurology Clinic |
Tennessee |
|
University of Texas Health Science Center at San Antonio |
Texas |
|
Houston Methodist |
Texas |
|
Texas Neurology |
Texas |
|
University of Virginia |
Virginia |
|
University of Washington |
Washington |
|
Medical College of Wisconsin |
Wisconsin |
HEALEY ALS Platform Trial Indirect Cost Policy
In executing the Master Clinical Trial Agreement (MCTA) to participate in the HEALEY ALS Platform Trial, Sites agree they will be paid indirect costs (IDC) at the rate at which the originating funding organization reimburses MGH. For payments made from internal MGH philanthropic funds, the IDC will be capped at 15% of total direct costs.
Reference Papers on Innovative Trial Design
Platform trials are trials where multiple drugs are tested at the same time, using specialized statistical tools.
Work With Us
Researchers interested in testing a therapy in the HEALEY ALS Platform Trial should contact us to discuss collaboration. We look forward to hearing from you.